In summary, both MAPK14 and ATF2 were identified as novel target genes of miR-622 in HCC, outlining this microRNA as a master regulator of the drug resistance associated MAPK14-ATF2 and RAS-RAF-ERK pathways. The gene discussed is ATF2; the disease is hepatocellular carcinoma.